OvaScience (OVAS) Names Christophe Couturier as CFO
- Wall Street stocks fall as weak GDP growth spreads rate-cut gloom
- Q1 US GDP shows surprise slowing and uncomfortable inflation
- Alphabet (GOOGL) soars 16% on Q1 results beat, first-ever dividend
- Meta shares dip on softer Q2 revenue guidance, elevated AI spending plans
- Oil settles higher as weak U.S. economic growth offset by supply concerns
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hasbro (HAS) brand strength sees earnings top expectations
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Rubrik (RBRK) Prices Upsized 23.5M Share IPO at $32/sh
- After-hours movers: Alphabet, Microsoft, Snap, Intel, and more
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
OvaScience Announces Executive Management Changes and Appointments to Further Drive Company’s Growth
September 6, 2016 4:05 PM EDTChristophe Couturier Named Chief Financial Officer
Karen Long Named Executive Vice President, Clinical and Regulatory Affairs and Quality Assurance
James Luterman, Ph.D. Promoted to Executive Vice President, Research and Development
WALTHAM, Mass.--(BUSINESS WIRE)-- OvaScienceSM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, today announced changes to its senior management team, reflecting the Companys continued evolution and global growth. Christophe Couturier has been named Chief Financial Officer, effective immediately. He... More